Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

eTRANSAFE – collaborative research project aimed at improving safety in drug development process

26.09.2017

The 40 million euro European project eTRANSAFE, to be kicked off at the end of September 2017, is aimed at speeding up the development of better and safer medicines for patients. Coordinated by the Fundació Institut Mar d'Investigacions Mèdiques (IMIM) and led by the pharmaceutical company Novartis, the project consortium is a public-private partnership of eight academic institutions, six SMEs, and twelve pharmaceutical companies. One of the project partners is Fraunhofer ITEM.

The five-year project “Enhancing Translational Safety Assessment through Integrative Knowledge Management” (eTRANSAFE) is aimed at developing an advanced data integration infrastructure together with innovative computational methods to improve safety assessment across the drug discovery and development process.


An aim of the project eTRANSAFE is to analyze whether and to what extent preclinical data enable reliable prediction of clinical findings.

Felix Schmitt, Fraunhofer ITEM

To this end, bioinformatic approaches shall be applied to shared preclinical and clinical data and the translatability of observed effects shall be systematically analyzed, thus enabling optimization of resources and development of safer medicines.

Fraunhofer ITEM’s assignment in the eTRANSAFE project is to evaluate whether and to what extent toxicological findings from preclinical data can be used to predict clinical findings. For this purpose, Fraunhofer ITEM toxicologists and physicians will work hand in hand. They will first analyze in detail the available preclinical data from existing databases such as eToxSys.

The aim is to gather insights, for example, into the time dependence of toxicological effects or possibilities of substance grouping. In the next stage, the predictivity of preclinical data for human clinical effects will be analyzed.

Depending on the availability and type of clinical data and a database (yet to be established), the investigations will be performed by analyzing individual case studies or by using statistical models. This development work is part of the project. Fraunhofer ITEM has many years of experience in analyzing preclinical data and querying databases such as the RepDose database (www.fraunhofer-repdose.de).

“The safety of new drug candidates in first clinical trials is extrapolated based on preclinical animal data. These extrapolations are made using solely the data generated for the project at hand, since a global and systematic analysis of predictivity of the entire collective historical data pool has never been made," says project leader François Pognan from Novartis. "It is often poorly known to what extent and frequency an observed effect in an animal species may translate into a human effect,” adds deputy leader Thomas Steger-Hartmann from Bayer.

Based on the experience gained in the previous eTOX project, the eTRANSAFE project will carry out key efforts in the field of data standardization and quality control. This will promote the development and implementation of relevant data sharing policies and procedures and at the same time will catalyze transformation of the existing concepts for drug safety modeling – from monolithic applications and isolated data repositories to an open, innovative system based on open standards, modular components, and data integration services.

Professor Ferran Sanz from Fundació IMIM, coordinator of the project, said: “eTRANSAFE will improve translational safety assessment and contribute to the key scientific policies, such as the reduce, replace, refine (3Rs) one and the FAIR principles for data sharing.”

eTRANSAFE is funded through the Innovative Medicines Initiative 2 Joint Undertaking (IMI 2), a public-private partnership between the European Union, represented by the European Commission, and the (bio)pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries Associations (EFPIA), supporting collaborative research projects.

Press contact
Fraunhofer ITEM
Dr. Cathrin Nastevska
Phone +49 511 5350-225
cathrin.nastevska@item.fraunhofer.de

Scientific contact:
Fraunhofer ITEM
Dr. Sylvia Escher
Phone +49 511 5350-330
sylvia.escher@item.fraunhofer.de

Weitere Informationen:

http://www.item.fraunhofer.de/en.html
http://www.etransafe.eu/

Fraunhofer ITEM Dr. Cathrin Nastevska | Fraunhofer-Gesellschaft

More articles from Life Sciences:

nachricht In focus: Peptides, the “little brothers and sisters” of proteins
12.11.2018 | Technische Universität Berlin

nachricht How to produce fluorescent nanoparticles for medical applications in a nuclear reactor
09.11.2018 | Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague)

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

Im Focus: Coping with errors in the quantum age

Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly

The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...

Im Focus: Nanorobots propel through the eye

Scientists developed specially coated nanometer-sized vehicles that can be actively moved through dense tissue like the vitreous of the eye. So far, the transport of nano-vehicles has only been demonstrated in model systems or biological fluids, but not in real tissue. The work was published in the journal Science Advances and constitutes one step further towards nanorobots becoming minimally-invasive tools for precisely delivering medicine to where it is needed.

Researchers of the “Micro, Nano and Molecular Systems” Lab at the Max Planck Institute for Intelligent Systems in Stuttgart, together with an international...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

In focus: Peptides, the “little brothers and sisters” of proteins

12.11.2018 | Life Sciences

Materials scientist creates fabric alternative to batteries for wearable devices

12.11.2018 | Materials Sciences

A two-atom quantum duet

12.11.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>